Skip to main content

IDWeek 2022 Main banner

Tweets by IDWeek 2022

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Nicolette Schuko, MS

AstraZeneca

Disclosure(s): AstraZeneca: Employee, Stocks/Bonds

Poster(s):

1110 - AZD7442 (Tixagevimab/Cilgavimab) Demonstrates Potent In Vitro Activity Against SARS-CoV-2 Spike Variants Identified in Circulation and in Prophylaxis Clinical Studies
Friday, October 21, 2022
12:15 PM – 1:30 PM US ET
1160 - Treatment-Emergent Viral Variants in the Phase 3 TACKLE Trial Investigating Efficacy and Safety of AZD7442 (Tixagevimab/Cilgavimab) for the Treatment of Mild to Moderate COVID-19 in Adults
Friday, October 21, 2022
12:15 PM – 1:30 PM US ET